CINRG randomized controlled trial of creatine and glutamine in Duchenne muscular dystrophy.
We tested the efficacy and safety of glutamine (0.6 gm/kg/day) and creatine (5 gm/day) in 50 ambulant boys with Duchenne muscular dystrophy in a 6-month, double-blind, placebo-controlled clinical trial. Drug efficacy was tested by measuring muscle strength manually (34 muscle groups) and quantitatively (10 muscle groups). Timed functional tests, functional parameters, and pulmonary function tests were secondary outcome measures. Although there was no statistically significant effect of either therapy based on manual and quantitative measurements of muscle strength, a disease-modifying effect of creatine in older Duchenne muscular dystrophy and creatine and glutamine in younger Duchenne muscular dystrophy cannot be excluded. Creatine and glutamine were well tolerated.
Children's National Medical Center, George Washington University, Washington, DC, USA. descolar@cnmcresearch.org
Diana M
DM
Escolar
Gunnar
G
Buyse
Erik
E
Henricson
Robert
R
Leshner
Julaine
J
Florence
Jill
J
Mayhew
Carolina
C
Tesi-Rocha
Ksenija
K
Gorni
Livia
L
Pasquali
Kantilal M
KM
Patel
Robert
R
McCarter
Jennifer
J
Huang
Thomas
T
Mayhew
Tulio
T
Bertorini
Jose
J
Carlo
Anne M
AM
Connolly
Paula R
PR
Clemens
Nathalie
N
Goemans
Susan T
ST
Iannaccone
Masanori
M
Igarashi
Yoram
Y
Nevo
Alan
A
Pestronk
S H
SH
Subramony
V V
VV
Vedanarayanan
Henry
H
Wessel
D002648:Child; D002675:Child, Preschool; D003401:Creatine / Q000627:therapeutic use*; D005973:Glutamine / Q000627:therapeutic use*; D006801:Humans; D008297:Male; D018482:Muscle, Skeletal / Q000187:drug effects*; D020388:Muscular Dystrophy, Duchenne / Q000188:drug therapy*; D012129:Respiratory Function Tests
D005973:Glutamine; D003401:Creatine